Jul 1
|
Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint
|
Jun 30
|
Asian Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
|
Jun 30
|
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
|
Jun 27
|
Asian Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Up 5% for Week
|
Jun 20
|
Zai Lab (ZLAB) Delivers Positive ZL-1503 Trial Results in Treatment of Atopic Dermatitis
|
Jun 17
|
Asian Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
|
Jun 2
|
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
|
May 31
|
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
|
May 30
|
Zai Lab Announces Participation in Investor Conferences in June 2025
|
Apr 15
|
All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy
|
Apr 14
|
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last?
|
Apr 14
|
Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025
|
Jan 23
|
FDA grants ODD status to Zai Lab’s lung cancer treatment
|
Jan 23
|
Why Is Andreas Halvorsen Bullish On Zai Lab Limited (ZLAB) Now?
|
Jan 23
|
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
|
Jan 21
|
High Growth Tech Stocks To Explore In January 2025
|
Jan 21
|
Here’s Why Analysts Are Bullish on Zai Lab Limited (ZLAB)
|
Jan 20
|
Market Sentiment Around Loss-Making Zai Lab Limited (NASDAQ:ZLAB)
|
Jan 17
|
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
|